查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
免疫組庫定序市場（按產品、技術、工作流程、應用、最終用戶和地區分類）—預測至 2030 年
市場調查報告書
商品編碼
1714900

免疫組庫定序市場（按產品、技術、工作流程、應用、最終用戶和地區分類）—預測至 2030 年

Immune Repertoire Sequencing Market by Product (Instrument, Software, Assay Kit & Reagent (TCR, BCR Kit)), Technology (Sequencing, Bioinformatics), Service (Data Analysis), Application (Research, Drug Discovery & Development) - Global Forecast to 2030
出版日期: | 出版商: MarketsandMarkets | 英文 371 Pages | 訂單完成後即時交付

價格

全球免疫組庫定序(IRS) 市場規模預計將從 2025 年的 3.34 億美元增至 2030 年的 5.65 億美元，預測期內的複合年成長率為 9.6%。

隨著技術進步提高了基於免疫測量的研究解決方案的效率、靈敏度和可擴展性，這個市場正在不斷擴大。 NGS 整合、自動化液體處理系統和高通量篩檢平台等技術創新正在實現更快、更準確的檢測結果。這些進步簡化了工作流程，減少了人工錯誤並提高了吞吐量，使 IRS 技術更易於研究和臨床應用，並且更可靠。此外，隨著對個人化和精準醫療的關注度不斷提高，醫療保健提供者和研究人員越來越需要檢測特定生物標記並針對個別患者量身定做治療方案的工具，從而推動對 IRS 解決方案的需求。這種向標靶治療的轉變將推動旨在支持伴同性診斷、治療監測和個人化治療策略的特定檢測套件和試劑的開發。因此，人們越來越需要能夠提供準確、以患者為中心的資料指南臨床決策和改善結果的免疫測量技術。

研究範圍
調查年份 2024-2030
基準年 2024
預測期 2024-2030
對價單位 金額（百萬美元）
部分 按產品、技術、工作流程、應用程式、最終用戶、地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

在預測期內，定序技術領域佔據免疫組庫定序產品市場的最大佔有率。

2024年，定序技術佔據IRS產品市場按技術分類的最大市場佔有率。定序技術是免疫組庫定序研究的核心。 NGS 技術的進步提高了讀取長度、吞吐量和周轉時間，同時大幅降低了每次運行的成本，使定序在臨床和研究環境中更具可擴展性和可訪問性。此外，主要企業在平台技術方面的不斷創新，實現了高效、易於使用的測序儀的商業化，支持廣泛的應用，包括免疫腫瘤學、感染疾病分析和疫苗開發。這一核心作用，加上學術和商業研究環境中的高採用率，使得定序技術成為最大的 IRS 產品市場。

在預測期內，學術研究機構在免疫組庫定序產品市場中佔據最終用戶最大的市場佔有率。

學術研究機構是 IRS 產品的最大最終用戶，包括檢測試劑套件、試劑、儀器和軟體。許多探索性和假設驅動的研究，包括免疫分析、生物標記發現和疾病機制闡明，正在嚴重依賴 IRS 技術的大學和學術醫療中心進行。學術機構對檢測試劑套件、試劑、定序設備和生物資訊軟體的需求達到了前所未有的高度，因為各種研究計畫都需要靈活、可擴展且精確的工具。此外，政府和研究機構對免疫學、腫瘤學和感染疾病研究的資金增加，推動了 IRS 技術在學術機構的廣泛應用。

預計在研究期間，亞太地區將成為免疫組定序市場成長最快的地區。

預計亞太地區的 IRS 市場將在預測期內實現最高成長率。這種高成長歸因於對醫療保健基礎設施建設的重視程度不斷提高以及對生物醫學研究的投資不斷增加。中國、印度、韓國和日本等國的政府正在撥出大量資金支持包括 IRS 在內的生命科學和精準醫療工作。此外，由於人口多樣化和營運成本低而具有巨大的成長潛力，主要區域公司增加投資也是支持該地區在預測期內快速成長的關鍵因素。

本報告研究了全球免疫組庫定序市場，並從產品、技術、工作流程、應用、最終用戶、區域趨勢和公司概況等方面對市場進行了詳細分析。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章重要考察

第5章市場概述

  • 介紹
  • 市場動態
  • 影響客戶業務的趨勢/中斷
  • 定價分析
  • 供應鏈分析
  • 價值鏈分析
  • 生態系分析
  • 技術分析
  • 專利分析
  • 貿易資料分析
  • 2025-2026 年重要會議與活動
  • 監管分析
  • 波特五力分析
  • 主要相關人員和採購標準
  • 投資金籌措場景
  • 人工智慧/生成式人工智慧對免疫組庫定序市場的影響

6. 免疫組庫定序市場（依產品）

  • 介紹
  • 檢測套件和試劑
  • 設備和軟體

7. 免疫組庫定序產品市場（依技術）

  • 介紹
  • 定序技術
  • 圖書館創建技術
  • 生物資訊學和資料分析技術

8. 免疫組庫定序服務市場（依工作流程）

  • 介紹
  • 定序服務
  • 資料分析服務
  • 定序服務

9. 免疫組庫定序市場（依應用）

  • 介紹
  • 研究
  • 藥物研發
  • 臨床診斷

第 10 章。免疫組庫定序產品市場（依最終用戶）

  • 介紹
  • 學術研究所
  • 製藥和生物技術公司
  • 其他

第 11 章免疫組庫定序服務市場（依最終用戶）

  • 介紹
  • 製藥和生物技術公司
  • 學術研究所
  • 其他

12. 免疫組庫定序市場（按地區）

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 其他
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他
  • 中東
    • 中東宏觀經濟展望
    • 海灣合作理事會國家
    • 其他
  • 非洲
    • 政府資金增加及擴大國際夥伴關係推動市場成長
    • 非洲宏觀經濟展望

第13章競爭格局

  • 介紹
  • 主要參與企業的策略/優勢，2022-2025
  • 2022-2024年收益分析
  • 2024年市場佔有率分析
  • 估值和財務指標
  • 品牌/產品比較
  • 公司估值矩陣：2024 年主要參與企業
  • 公司估值矩陣：Start-Ups/中小企業，2024 年
  • 競爭場景

第14章 公司簡介

  • 主要參與企業
    • ILLUMINA, INC.
    • THERMO FISHER SCIENTIFIC INC.
    • PACBIO
    • OXFORD NANOPORE TECHNOLOGIES PLC
    • 10X GENOMICS
    • QIAGEN
    • AGILENT TECHNOLOGIES
    • DANAHER CORPORATION
    • TAKARA BIO INC.
    • ADAPTIVE BIOTECHNOLOGIES
    • BGI GROUP
    • TECAN TRADING AG
    • AZENTA US INC.
    • PERSONALIS, INC.
    • CREATIVE BIOLABS
  • 其他公司
    • CELEMICS, INC.
    • CELLCARTA
    • IREPERTOIRE, INC.
    • NEW ENGLAND BIOLABS
    • CERBA RESEARCH
    • CEGAT GMBH
    • ELEMENT BIOSCIENCES
    • SEQALIS
    • SYNBIO TECHNOLOGIES
    • MEDGENOME
    • ENPICOM

第15章 附錄

Product Code: BT 9352

The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period. This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes.

Scope of the Report
Years Considered for the Study2024-2030
Base Year2024
Forecast Period2024-2030
Units ConsideredValue (USD million)
SegmentsProduct (Technology, End User), Service (Workflow, End User), Application
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East, and Africa

The sequencing technology segment held the largest share in the immune repertoire sequencing products market, by technology, during the forecast period.

In 2024, sequencing technology held the largest market within the IRS products market by technology. Sequencing technologies are the core enablers of immune repertoire sequencing studies. Advances in NGS technologies have significantly lowered the cost per run while improving read lengths, throughput, and turnaround time-making sequencing more scalable and accessible across clinical and research settings. Moreover, the continuous innovation in platform technologies by key industry players has led to the commercialization of highly efficient, user-friendly sequencers that support a broad array of applications, including immuno-oncology, infectious disease profiling, and vaccine development. Thus, this central role, coupled with high adoption rates in both academic and commercial research environments, positions sequencing technology as the largest in the IRS product market.

Academic & research institutes held the largest market share in the immune repertoire sequencing products market, by end user, during the forecast period.

Academic & research institutes are the largest end users of IRS products, such as assay kits & reagents, instruments, and software. Universities and academic medical centers conduct many exploratory and hypothesis-driven studies that rely heavily on IRS technologies for immune profiling, biomarker discovery, and understanding disease mechanisms. The demand for assay kits, reagents, sequencing instruments, and bioinformatics software is consistently high in academia, where diverse research programs require flexible, scalable, and precise tools. Moreover, increased government and institutional funding for immunology, oncology, and infectious disease research further supports the widespread adoption of IRS technologies in academic settings.

The Asia Pacific is expected to be the fastest growing region in the immune repertoire sequencing market during the study period.

The Asia Pacific IRS market is projected to register the highest growth rate during the forecast period. This high growth is attributed to the growing emphasis on healthcare infrastructure development and increased investments in biomedical research. Governments across countries such as China, India, South Korea, and Japan allocate substantial funding to support life sciences and precision medicine initiatives, including the IRS. Additionally, increasing investments of key regional players, considering the enormous growth potential mainly due to the diverse population and low operational costs, is another key factor supporting the region's fastest growth during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type: Tier 1-44%, Tier 2-32%, and Tier 3-24%
  • By Designation: (Managers)-45%, (CXOs, Directors)-30%, and (Executives)-25%
  • By Region: North America-40%, Europe-25%, Asia-Pacific-20%, Rest of the World-15%

List of Companies Profiled in the Report:

  • Illumina, Inc. (US)
  • Thermo Fisher Scientific Inc. (US)
  • PacBio (US)
  • Oxford Nanopore Technologies PLC (UK)
  • 10X Genomics (US)
  • QIAGEN (Netherlands)
  • Agilent Technologies (US)
  • Danaher Corporation (US)
  • Takara Bio Inc. (Japan)
  • Adaptive Biotechnologies (US)
  • BGI Group (China)
  • Tecan Trading AG (Switzerland)
  • Azenta US Inc. (US)
  • Personalis, Inc. (US)
  • Creative Biolabs (US)
  • Celemics, Inc. (South Korea)
  • CellCarta (Canada)
  • iRepertoire, Inc. (US)
  • New England Biolabs (US)
  • Cerba Research (Belgium)
  • CeGat GmbH (Germany)
  • Element Biosciences (US)
  • Seqalis (Belgium)
  • Synbio Technologies (China)
  • MedGenome (US)
  • Enpicom (Netherlands)

Research Coverage:

This report provides a detailed picture of the global IRS market. It aims to estimate the market's size and future growth potential across different segments such as the product, service, application product-technology, product-end user, service-end user, and region. The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the IRS market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, services, key strategies, partnerships, agreements, new product and service launches, mergers and acquisitions, and recent developments associated with the immune repertoire sequencing market. This report covers the competitive analysis of upcoming startups in the immune repertoire sequencing market ecosystem.

Reasons to Buy this Report :

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall immune repertoire sequencing market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

  • Analysis of key drivers (Increasing technological advancements, growing focus on precision/personalized medicines, increasing use of IRS in organ transplantation), restraints (need for high capital investments), opportunities (integration of AI and ML in IRS), and challenges (variations in regulatory frameworks and international trade dynamics) influencing the growth of the immune repertoire sequencing market.
  • Product/ Service Development/Innovation: Detailed insights on upcoming technologies and new product and service launches in the immune repertoire sequencing market
  • Market Development: Comprehensive information about lucrative markets - the report analyses the immune repertoire sequencing market across varied regions.
  • Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the immune repertoire sequencing market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product and service offerings of leading players in the immune repertoire sequencing market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key objectives of secondary research
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries
      • 2.1.2.2 Key objectives of primary research
  • 2.2 MARKET ESTIMATION METHODOLOGY
    • 2.2.1 GLOBAL MARKET ESTIMATION
      • 2.2.1.1 Bottom-up approach
      • 2.2.1.2 Insights from primary experts
    • 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
  • 2.3 MARKET GROWTH RATE PROJECTION
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RESEARCH LIMITATIONS
  • 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

  • 4.1 IMMUNE REPERTOIRE SEQUENCING MARKET OVERVIEW
  • 4.2 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT AND COUNTRY
  • 4.3 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET SHARE, BY TECHNOLOGY, 2025 VS. 2030
  • 4.4 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET SHARE, BY END USER, 2025
  • 4.5 IMMUNE REPERTOIRE SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Increasing technological advancements
      • 5.2.1.2 Growing focus on personalized/precision medicines
      • 5.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring
      • 5.2.1.4 Increasing applications in autoimmune disease research
      • 5.2.1.5 Rising focus on cancer immunotherapy research
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Need for high capital investments
      • 5.2.2.2 Limited clinical adoption and validation
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Integration of AI and ML into immune repertoire sequencing
      • 5.2.3.2 Increasing applications in vaccine development
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Variations in regulatory frameworks and international trade dynamics
      • 5.2.4.2 Lack of workflow and data standardization
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.2 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024
  • 5.5 SUPPLY CHAIN ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
    • 5.7.1 ROLE IN ECOSYSTEM
      • 5.7.1.1 Product providers
      • 5.7.1.2 Service providers
      • 5.7.1.3 End users
      • 5.7.1.4 Regulatory bodies
  • 5.8 TECHNOLOGY ANALYSIS
    • 5.8.1 KEY TECHNOLOGIES
      • 5.8.1.1 High-throughput sequencing
      • 5.8.1.2 Nanopore sequencing
      • 5.8.1.3 Single-molecule real-time (SMRT) sequencing
    • 5.8.2 COMPLEMENTARY TECHNOLOGIES
      • 5.8.2.1 Bioinformatics and data analysis platforms
      • 5.8.2.2 Multiplex PCR
      • 5.8.2.3 5'RACE
    • 5.8.3 ADJACENT TECHNOLOGIES
      • 5.8.3.1 Multi-omics integration
      • 5.8.3.2 Spatial genomics and transcriptomics
      • 5.8.3.3 Single-cell sequencing technologies
  • 5.9 PATENT ANALYSIS
  • 5.10 TRADE DATA ANALYSIS
    • 5.10.1 IMPORT DATA FOR HS CODE 3822, 2020-2024
    • 5.10.2 EXPORT DATA FOR HS CODE 3822, 2020-2024
  • 5.11 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.12 REGULATORY ANALYSIS
    • 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
    • 5.12.2 REGULATORY FRAMEWORK
      • 5.12.2.1 North America
        • 5.12.2.1.1 US
        • 5.12.2.1.2 Canada
      • 5.12.2.2 Europe
        • 5.12.2.2.1 UK
      • 5.12.2.3 Asia Pacific
        • 5.12.2.3.1 China
        • 5.12.2.3.2 Japan
        • 5.12.2.3.3 South Korea
        • 5.12.2.3.4 Australia
        • 5.12.2.3.5 India
        • 5.12.2.3.6 Rest of Asia Pacific
  • 5.13 PORTER'S FIVE FORCES ANALYSIS
    • 5.13.1 THREAT OF NEW ENTRANTS
    • 5.13.2 THREAT OF SUBSTITUTES
    • 5.13.3 BARGAINING POWER OF BUYERS
    • 5.13.4 BARGAINING POWER OF SUPPLIERS
    • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 KEY BUYING CRITERIA
  • 5.15 INVESTMENT & FUNDING SCENARIO
  • 5.16 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET

6 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 ASSAY KITS & REAGENTS
    • 6.2.1 TCR KITS
      • 6.2.1.1 Human TCR kits
        • 6.2.1.1.1 Increased demand for high-throughput TCR profiling in oncology and immunotherapy research to fuel market growth
      • 6.2.1.2 Mouse TCR kits
        • 6.2.1.2.1 Rising demand for TCR profiling in preclinical studies and growing need for standardized workflows to drive segment
    • 6.2.2 BCR KITS
      • 6.2.2.1 Human BCR kits
        • 6.2.2.1.1 Increasing demand for high-throughput profiling and rising focus on immunology research to fuel uptake
      • 6.2.2.2 Mouse BCR kits
        • 6.2.2.2.1 High demand for antibody discovery and preclinical research to boost segment growth
    • 6.2.3 OTHER ASSAY KITS & REAGENTS
  • 6.3 INSTRUMENTS & SOFTWARE
    • 6.3.1 TECHNOLOGICAL ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND COMPANION DIAGNOSTICS TO AUGMENT MARKET GROWTH

7 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY

  • 7.1 INTRODUCTION
  • 7.2 SEQUENCING TECHNOLOGIES
    • 7.2.1 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES
      • 7.2.1.1 Increasing adoption of TCR sequencing for inflammation-mediated diseases to support segment growth
    • 7.2.2 SINGLE-CELL SEQUENCING TECHNOLOGIES
      • 7.2.2.1 Need for integrative analysis of immune receptor repertoires and transcriptional states to spur market growth
  • 7.3 LIBRARY PREPARATION TECHNOLOGIES
    • 7.3.1 HIGH DEMAND FOR COST-EFFICIENT AND HIGH-THROUGHPUT IMMUNE REPERTOIRE PROFILING TO FUEL MARKET GROWTH
  • 7.4 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES
    • 7.4.1 GROWING FOCUS ON RESEARCH TO DRIVE DEMAND FOR ADVANCED BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES

8 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW

  • 8.1 INTRODUCTION
  • 8.2 SEQUENCING SERVICES
    • 8.2.1 RISING NEED FOR HIGH-RESOLUTION IMMUNE PROFILING IN CANCER AND AUTOIMMUNE DISEASES TO DRIVE MARKET
  • 8.3 DATA ANALYSIS SERVICES
    • 8.3.1 HIGH DEMAND FOR STANDARDIZED NGS DATA INTERPRETATION AND CROSS-SAMPLE COMPARABILITY TO DRIVE MARKET
  • 8.4 PRE-SEQUENCING SERVICES
    • 8.4.1 INCREASED REQUIREMENT FOR STANDARDIZED WORKFLOWS FOR ADDRESSING PCR BIAS TO AUGMENT MARKET GROWTH

9 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION

  • 9.1 INTRODUCTION
  • 9.2 RESEARCH APPLICATIONS
    • 9.2.1 LOW SEQUENCING COSTS AND INCREASED NEED TO RESOLVE CELLULAR HETEROGENEITY AT HIGH RESOLUTION TO DRIVE MARKET
  • 9.3 DRUG DISCOVERY & DEVELOPMENT
    • 9.3.1 INCREASED NEED FOR TARGETED THERAPIES AND ADVANCEMENTS IN HIGH-THROUGHPUT SCREENING TO AID MARKET GROWTH
  • 9.4 CLINICAL DIAGNOSTICS
    • 9.4.1 GROWING DEMAND FOR EARLY DETECTION OF SUBCLINICAL CONDITIONS TO AID MARKET GROWTH

10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER

  • 10.1 INTRODUCTION
  • 10.2 ACADEMIC & RESEARCH INSTITUTES
    • 10.2.1 INCREASED FUNDING FOR IMMUNOLOGICAL RESEARCH AND IMMUNOGENOMICS TO DRIVE MARKET
  • 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 10.3.1 RISING FOCUS ON DRUG DISCOVERY AND THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
  • 10.4 OTHER END USERS

11 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER

  • 11.1 INTRODUCTION
  • 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 11.2.1 NEED TO REDUCE IN-HOUSE INFRASTRUCTURE COSTS AND MEET SCALABILITY DEMANDS TO BOOST MARKET GROWTH
  • 11.3 ACADEMIC & RESEARCH INSTITUTES
    • 11.3.1 INCREASING FUNDING FOR GENOMIC RESEARCH AND GROWING DEMAND FOR COMPLEX DATA ANALYSIS TO AID MARKET GROWTH
  • 11.4 OTHER END USERS

12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION

  • 12.1 INTRODUCTION
  • 12.2 NORTH AMERICA
    • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 12.2.2 US
      • 12.2.2.1 US to dominate North American market during forecast period
    • 12.2.3 CANADA
      • 12.2.3.1 Presence of advanced research facilities and favorable government-funded genomic studies to spur market growth
  • 12.3 EUROPE
    • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 12.3.2 GERMANY
      • 12.3.2.1 Technological advancements in RNA sequencing to fuel market growth
    • 12.3.3 UK
      • 12.3.3.1 Increased cross-sector partnerships and advancements in AI tools for large sequencing datasets to boost market growth
    • 12.3.4 FRANCE
      • 12.3.4.1 Public-private collaborations and increased funding for advanced genomic infrastructure to aid market growth
    • 12.3.5 ITALY
      • 12.3.5.1 High investments in genomic research to drive market
    • 12.3.6 SPAIN
      • 12.3.6.1 Increased government investments in precision medicine, genomic medicine, and data science to propel market growth
    • 12.3.7 REST OF EUROPE
  • 12.4 ASIA PACIFIC
    • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 12.4.2 CHINA
      • 12.4.2.1 Rising incidence of chronic diseases and increasing collaborations among industry stakeholders to drive market
    • 12.4.3 JAPAN
      • 12.4.3.1 Increasing research on long-read and biomolecular sequencing to aid market growth
    • 12.4.4 INDIA
      • 12.4.4.1 Advancements in genomic research and focus on industry-academia collaborations to expedite market growth
    • 12.4.5 SOUTH KOREA
      • 12.4.5.1 Favorable government initiatives and investment in sequencing technologies to boost market growth
    • 12.4.6 AUSTRALIA
      • 12.4.6.1 Increased research funding and favorable government initiatives to drive market
    • 12.4.7 REST OF ASIA PACIFIC
  • 12.5 LATIN AMERICA
    • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 12.5.2 BRAZIL
      • 12.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market growth
    • 12.5.3 MEXICO
      • 12.5.3.1 High geriatric population and advancements in precision medicine research to support market growth
    • 12.5.4 REST OF LATIN AMERICA
  • 12.6 MIDDLE EAST
    • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 12.6.2 GCC COUNTRIES
      • 12.6.2.1 Favorable government initiatives to drive drug development and clinical research
    • 12.6.3 REST OF MIDDLE EAST
  • 12.7 AFRICA
    • 12.7.1 RISING GOVERNMENT FUNDING AND INCREASING INTERNATIONAL PARTNERSHIPS TO FAVOR MARKET GROWTH
    • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

  • 13.1 INTRODUCTION
  • 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
  • 13.3 REVENUE ANALYSIS, 2022-2024
  • 13.4 MARKET SHARE ANALYSIS, 2024
  • 13.5 COMPANY VALUATION & FINANCIAL METRICS
    • 13.5.1 COMPANY VALUATION
    • 13.5.2 FINANCIAL METRICS
  • 13.6 BRAND/PRODUCT COMPARISON
  • 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 13.7.1 STARS
    • 13.7.2 EMERGING LEADERS
    • 13.7.3 PERVASIVE PLAYERS
    • 13.7.4 PARTICIPANTS
    • 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 13.7.5.1 Company footprint
      • 13.7.5.2 Region footprint
      • 13.7.5.3 Product and service footprint
      • 13.7.5.4 Application footprint
  • 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 13.8.1 PROGRESSIVE COMPANIES
    • 13.8.2 RESPONSIVE COMPANIES
    • 13.8.3 DYNAMIC COMPANIES
    • 13.8.4 STARTING BLOCKS
    • 13.8.5 COMPETITIVE BENCHMARKING
      • 13.8.5.1 Detailed list of key startups/SMEs
      • 13.8.5.2 Competitive benchmarking of key startups/SMEs
  • 13.9 COMPETITIVE SCENARIO
    • 13.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES
    • 13.9.2 DEALS
    • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

  • 14.1 KEY PLAYERS
    • 14.1.1 ILLUMINA, INC.
      • 14.1.1.1 Business overview
      • 14.1.1.2 Products/Services/Solutions offered
      • 14.1.1.3 Recent developments
        • 14.1.1.3.1 Product launches/approvals/upgrades
        • 14.1.1.3.2 Deals
        • 14.1.1.3.3 Expansions
      • 14.1.1.4 MnM view
        • 14.1.1.4.1 Key strengths
        • 14.1.1.4.2 Strategic choices
        • 14.1.1.4.3 Weaknesses & competitive threats
    • 14.1.2 THERMO FISHER SCIENTIFIC INC.
      • 14.1.2.1 Business overview
      • 14.1.2.2 Products/Services/Solutions offered
      • 14.1.2.3 Recent developments
        • 14.1.2.3.1 Product launches/approvals/upgrades
        • 14.1.2.3.2 Deals
        • 14.1.2.3.3 Expansions
      • 14.1.2.4 MnM view
        • 14.1.2.4.1 Key strengths
        • 14.1.2.4.2 Strategic choices
        • 14.1.2.4.3 Weaknesses & competitive threats
    • 14.1.3 PACBIO
      • 14.1.3.1 Business overview
      • 14.1.3.2 Products/Services/Solutions offered
      • 14.1.3.3 Recent developments
        • 14.1.3.3.1 Product launches/approvals/upgrades
        • 14.1.3.3.2 Deals
        • 14.1.3.3.3 Expansions
      • 14.1.3.4 MnM view
        • 14.1.3.4.1 Key strengths
        • 14.1.3.4.2 Strategic choices
        • 14.1.3.4.3 Weaknesses & competitive threats
    • 14.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
      • 14.1.4.1 Business overview
      • 14.1.4.2 Products/Services/Solutions offered
      • 14.1.4.3 Recent developments
        • 14.1.4.3.1 Product launches/approvals/upgrades
        • 14.1.4.3.2 Deals
      • 14.1.4.4 MnM view
        • 14.1.4.4.1 Key strengths
        • 14.1.4.4.2 Strategic choices
        • 14.1.4.4.3 Weaknesses & competitive threats
    • 14.1.5 10X GENOMICS
      • 14.1.5.1 Business overview
      • 14.1.5.2 Products/Services/Solutions offered
      • 14.1.5.3 Recent developments
        • 14.1.5.3.1 Product launches/approvals/upgrades
      • 14.1.5.4 MnM view
        • 14.1.5.4.1 Key strengths
        • 14.1.5.4.2 Strategic choices
        • 14.1.5.4.3 Weaknesses & competitive threats
    • 14.1.6 QIAGEN
      • 14.1.6.1 Business overview
      • 14.1.6.2 Products/Services/Solutions offered
      • 14.1.6.3 Recent developments
        • 14.1.6.3.1 Product launches/approvals/upgrades
        • 14.1.6.3.2 Deals
        • 14.1.6.3.3 Expansions
    • 14.1.7 AGILENT TECHNOLOGIES
      • 14.1.7.1 Business overview
      • 14.1.7.2 Products/Services/Solutions offered
      • 14.1.7.3 Recent developments
        • 14.1.7.3.1 Deals
        • 14.1.7.3.2 Expansions
    • 14.1.8 DANAHER CORPORATION
      • 14.1.8.1 Business overview
      • 14.1.8.2 Products/Services/Solutions offered
      • 14.1.8.3 Recent developments
        • 14.1.8.3.1 Deals
    • 14.1.9 TAKARA BIO INC.
      • 14.1.9.1 Business overview
      • 14.1.9.2 Products/Services/Solutions offered
      • 14.1.9.3 Recent developments
        • 14.1.9.3.1 Deals
    • 14.1.10 ADAPTIVE BIOTECHNOLOGIES
      • 14.1.10.1 Business overview
      • 14.1.10.2 Products/Services/Solutions offered
    • 14.1.11 BGI GROUP
      • 14.1.11.1 Business overview
      • 14.1.11.2 Products/Services/Solutions offered
      • 14.1.11.3 Recent developments
        • 14.1.11.3.1 Product launches/approvals/upgrades
        • 14.1.11.3.2 Deals
        • 14.1.11.3.3 Other developments
    • 14.1.12 TECAN TRADING AG
      • 14.1.12.1 Business overview
      • 14.1.12.2 Products/Services/Solutions offered
      • 14.1.12.3 Recent developments
        • 14.1.12.3.1 Deals
    • 14.1.13 AZENTA US INC.
      • 14.1.13.1 Business overview
      • 14.1.13.2 Products/Services/Solutions offered
    • 14.1.14 PERSONALIS, INC.
      • 14.1.14.1 Business overview
      • 14.1.14.2 Products/Services/Solutions offered
      • 14.1.14.3 Recent developments
        • 14.1.14.3.1 Deals
        • 14.1.14.3.2 Other developments
    • 14.1.15 CREATIVE BIOLABS
      • 14.1.15.1 Business overview
      • 14.1.15.2 Products/Services/Solutions offered
  • 14.2 OTHER PLAYERS
    • 14.2.1 CELEMICS, INC.
    • 14.2.2 CELLCARTA
    • 14.2.3 IREPERTOIRE, INC.
    • 14.2.4 NEW ENGLAND BIOLABS
    • 14.2.5 CERBA RESEARCH
    • 14.2.6 CEGAT GMBH
    • 14.2.7 ELEMENT BIOSCIENCES
    • 14.2.8 SEQALIS
    • 14.2.9 SYNBIO TECHNOLOGIES
    • 14.2.10 MEDGENOME
    • 14.2.11 ENPICOM

15 APPENDIX

  • 15.1 DISCUSSION GUIDE
  • 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 15.3 CUSTOMIZATION OPTIONS
  • 15.4 RELATED REPORTS
  • 15.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 IMPACT ANALYSIS OF SUPPLY- AND DEMAND-SIDE FACTORS
  • TABLE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RISK ANALYSIS
  • TABLE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: IMPACT ANALYSIS
  • TABLE 5 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
  • TABLE 6 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD)
  • TABLE 7 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT PROVIDERS
  • TABLE 8 IMMUNE REPERTOIRE SEQUENCING MARKET: SERVICE PROVIDERS
  • TABLE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: END USERS
  • TABLE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: REGULATORY BODIES
  • TABLE 11 INNOVATIONS AND PATENT REGISTRATIONS, 2024-2025
  • TABLE 12 IMPORT DATA FOR HS CODE 3822, BY REGION, 2020-2024 (USD)
  • TABLE 13 EXPORT DATA FOR HS CODE 3822, BY REGION, 2020-2024 (USD)
  • TABLE 14 IMMUNE REPERTOIRE SEQUENCING MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2025-DECEMBER 2026
  • TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER'S FIVE FORCES
  • TABLE 20 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS (%)
  • TABLE 21 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET)
  • TABLE 22 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET)
  • TABLE 23 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 24 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 25 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 26 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 27 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 28 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 29 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 30 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 31 TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 32 TCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 33 NORTH AMERICA: TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 34 EUROPE: TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 35 ASIA PACIFIC: TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 36 LATIN AMERICA: TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 37 MIDDLE EAST: TCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 38 HUMAN TCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 39 NORTH AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 40 EUROPE: HUMAN TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 41 ASIA PACIFIC: HUMAN TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 42 LATIN AMERICA: HUMAN TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 43 MIDDLE EAST: HUMAN TCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 44 MOUSE TCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 45 NORTH AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 46 EUROPE: MOUSE TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 47 ASIA PACIFIC: MOUSE TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 48 LATIN AMERICA: MOUSE TCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 49 MIDDLE EAST: MOUSE TCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 50 BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 51 BCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 52 NORTH AMERICA: BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 53 EUROPE: BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 54 ASIA PACIFIC: BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 55 LATIN AMERICA: BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 56 MIDDLE EAST: BCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 57 HUMAN BCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 58 NORTH AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 59 EUROPE: HUMAN BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 60 ASIA PACIFIC: HUMAN BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 61 LATIN AMERICA: HUMAN BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 62 MIDDLE EAST: HUMAN BCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 63 MOUSE BCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 64 NORTH AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 65 EUROPE: MOUSE BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: MOUSE BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 67 LATIN AMERICA: MOUSE BCR KITS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 68 MIDDLE EAST: MOUSE BCR KITS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 69 OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 70 NORTH AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 71 EUROPE: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 72 ASIA PACIFIC: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 73 LATIN AMERICA: OTHER ASSAY KITS & REAGENTS MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 74 MIDDLE EAST: OTHER ASSAY KITS & REAGENTS MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 75 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 76 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 77 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 78 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 79 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 80 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR INSTRUMENTS & SOFTWARE, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 81 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 82 SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 83 SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 84 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 85 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 86 ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 87 LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 88 MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 89 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 90 NORTH AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 91 EUROPE: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 92 ASIA PACIFIC: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 93 LATIN AMERICA: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 94 MIDDLE EAST: BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 95 SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 96 NORTH AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 97 EUROPE: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 98 ASIA PACIFIC: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 99 LATIN AMERICA: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 100 MIDDLE EAST: SINGLE-CELL SEQUENCING TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 101 LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 102 NORTH AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 103 EUROPE: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 104 ASIA PACIFIC: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 105 LATIN AMERICA: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 106 MIDDLE EAST: LIBRARY PREPARATION TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 107 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 108 NORTH AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 109 EUROPE: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 110 ASIA PACIFIC: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 111 LATIN AMERICA: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 112 MIDDLE EAST: BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 113 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 114 SEQUENCING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 115 NORTH AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 116 EUROPE: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 117 ASIA PACIFIC: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 118 LATIN AMERICA: SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 119 MIDDLE EAST: SEQUENCING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 120 DATA ANALYSIS SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 121 NORTH AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 122 EUROPE: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 123 ASIA PACIFIC: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 124 LATIN AMERICA: DATA ANALYSIS SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 125 MIDDLE EAST: DATA ANALYSIS SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 126 PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 127 NORTH AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 128 EUROPE: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 129 ASIA PACIFIC: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 130 LATIN AMERICA: PRE-SEQUENCING SERVICES MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 131 MIDDLE EAST: PRE-SEQUENCING SERVICES MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 132 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 133 IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 134 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 135 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 136 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 137 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 138 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 139 IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 140 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 141 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 142 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 143 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 144 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 145 IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 146 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 147 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 148 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 149 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 150 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 151 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 152 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 153 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 154 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 155 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 156 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 157 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 158 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 159 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 160 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 161 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 162 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 163 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 164 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 165 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 166 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 167 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 168 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 169 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 170 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 171 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 172 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 173 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 174 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 175 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 176 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 177 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 178 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 179 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 180 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 181 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 182 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 183 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 184 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 185 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 186 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 187 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 188 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 189 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 190 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 191 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 192 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 193 NORTH AMERICA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 194 NORTH AMERICA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 195 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 196 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 197 NORTH AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 198 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 199 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 200 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 201 NORTH AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 202 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 203 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 204 US: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 205 US: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 206 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 207 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 208 US: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 209 US: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 210 US: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 211 US: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 212 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 213 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 214 CANADA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 215 CANADA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 216 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 217 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 218 CANADA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 219 CANADA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 220 CANADA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 221 CANADA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 222 EUROPE: KEY MACROECONOMIC INDICATORS
  • TABLE 223 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 224 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 225 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 226 EUROPE: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 227 EUROPE: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 228 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 229 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 230 EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 231 EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 232 EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 233 EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 234 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 235 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 236 GERMANY: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 237 GERMANY: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 238 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 239 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 240 GERMANY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 241 GERMANY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 242 GERMANY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 243 GERMANY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 244 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 245 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 246 UK: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 247 UK: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 248 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 249 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 250 UK: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 251 UK: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 252 UK: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 253 UK: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 254 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 255 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 256 FRANCE: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 257 FRANCE: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 258 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 259 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 260 FRANCE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 261 FRANCE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 262 FRANCE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 263 FRANCE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 264 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 265 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 266 ITALY: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 267 ITALY: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 268 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 269 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 270 ITALY: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 271 ITALY: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 272 ITALY: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 273 ITALY: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 274 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 275 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 276 SPAIN: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 277 SPAIN: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 278 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 279 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 280 SPAIN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 281 SPAIN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 282 SPAIN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 283 SPAIN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 284 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 285 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 286 REST OF EUROPE: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 287 REST OF EUROPE: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 288 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 289 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 290 REST OF EUROPE: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 291 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 292 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER,2023-2030 (USD MILLION)
  • TABLE 293 REST OF EUROPE: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 294 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 295 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 296 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 297 ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 298 ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 299 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 300 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 301 ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 302 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 303 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 304 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 305 ASIA PACIFIC: KEY MACROECONOMIC INDICATORS
  • TABLE 306 CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 307 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 308 CHINA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 309 CHINA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 310 CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 311 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 312 CHINA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 313 CHINA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 314 CHINA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 315 CHINA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 316 JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 317 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 318 JAPAN: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 319 JAPAN: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 320 JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 321 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 322 JAPAN: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 323 JAPAN: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 324 JAPAN: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 325 JAPAN: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 326 INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 327 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 328 INDIA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 329 INDIA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 330 INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 331 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 332 INDIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 333 INDIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 334 INDIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 335 INDIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 336 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 337 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 338 SOUTH KOREA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 339 SOUTH KOREA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 340 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 341 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 342 SOUTH KOREA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 343 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 344 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 345 SOUTH KOREA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 346 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 347 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 348 AUSTRALIA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 349 AUSTRALIA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 350 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 351 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 352 AUSTRALIA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 353 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 354 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 355 AUSTRALIA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 356 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 357 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 358 REST OF ASIA PACIFIC: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 359 REST OF ASIA PACIFIC: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 360 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 361 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 362 REST OF ASIA PACIFIC: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 363 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 364 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 365 REST OF ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 366 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY COUNTRY, 2023-2030 (USD MILLION)
  • TABLE 367 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 368 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 369 LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 370 LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 371 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 372 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 373 LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 374 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 375 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 376 LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 377 LATIN AMERICA: KEY MACROECONOMIC INDICATORS
  • TABLE 378 BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 379 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 380 BRAZIL: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 381 BRAZIL: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 382 BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 383 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 384 BRAZIL: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 385 BRAZIL: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 386 BRAZIL: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 387 BRAZIL: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 388 MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 389 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 390 MEXICO: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 391 MEXICO: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 392 MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 393 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 394 MEXICO: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 395 MEXICO: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 396 MEXICO: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 397 MEXICO: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 398 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 399 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 400 REST OF LATIN AMERICA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 401 REST OF LATIN AMERICA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 402 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 403 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 404 REST OF LATIN AMERICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 405 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 406 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 407 REST OF LATIN AMERICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 408 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION, 2023-2030 (USD MILLION)
  • TABLE 409 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 410 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 411 MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 412 MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 413 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 414 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 415 MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 416 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 417 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 418 MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 419 MIDDLE EAST: KEY MACROECONOMIC INDICATORS
  • TABLE 420 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 421 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 422 GCC COUNTRIES: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 423 GCC COUNTRIES: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 424 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 425 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 426 GCC COUNTRIES: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 427 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 428 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 429 GCC COUNTRIES: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 430 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 431 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 432 REST OF MIDDLE EAST: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 433 REST OF MIDDLE EAST: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 434 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 435 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 436 REST OF MIDDLE EAST: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 437 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 438 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 439 REST OF MIDDLE EAST: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 440 AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2023-2030 (USD MILLION)
  • TABLE 441 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET FOR ASSAY KITS & REAGENTS, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 442 AFRICA: TCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 443 AFRICA: BCR KITS MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 444 AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2023-2030 (USD MILLION)
  • TABLE 445 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2023-2030 (USD MILLION)
  • TABLE 446 AFRICA: SEQUENCING TECHNOLOGIES MARKET, BY TYPE, 2023-2030 (USD MILLION)
  • TABLE 447 AFRICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2023-2030 (USD MILLION)
  • TABLE 448 AFRICA: IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 449 AFRICA: IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2023-2030 (USD MILLION)
  • TABLE 450 AFRICA: KEY MACROECONOMIC INDICATORS
  • TABLE 451 IMMUNE REPERTOIRE SEQUENCING MARKET: OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS, 2022-2025
  • TABLE 452 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: DEGREE OF COMPETITION, 2024
  • TABLE 453 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET: DEGREE OF COMPETITION, 2024
  • TABLE 454 IMMUNE REPERTOIRE SEQUENCING MARKET: REGION FOOTPRINT
  • TABLE 455 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT AND SERVICE FOOTPRINT
  • TABLE 456 IMMUNE REPERTOIRE SEQUENCING MARKET: APPLICATION FOOTPRINT
  • TABLE 457 IMMUNE REPERTOIRE SEQUENCING MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 458 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES
  • TABLE 459 IMMUNE REPERTOIRE SEQUENCING MARKET: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 460 IMMUNE REPERTOIRE SEQUENCING MARKET: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 461 IMMUNE REPERTOIRE SEQUENCING MARKET: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 462 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 463 ILLUMINA, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 464 ILLUMINA, INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 465 ILLUMINA, INC.: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 466 ILLUMINA, INC.: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 467 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 468 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 469 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 470 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 471 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 472 PACBIO: COMPANY OVERVIEW
  • TABLE 473 PACBIO: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 474 PACBIO: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 475 PACBIO: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 476 PACBIO: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 477 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY OVERVIEW
  • TABLE 478 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCTS/SERVICES/ SOLUTIONS OFFERED
  • TABLE 479 OXFORD NANOPORE TECHNOLOGIES PLC: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 480 OXFORD NANOPORE TECHNOLOGIES PLC: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 481 10X GENOMICS: COMPANY OVERVIEW
  • TABLE 482 10X GENOMICS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 483 10X GENOMICS: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 484 QIAGEN: COMPANY OVERVIEW
  • TABLE 485 QIAGEN: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 486 QIAGEN: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 487 QIAGEN: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 488 QIAGEN: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 489 AGILENT TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 490 AGILENT TECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 491 AGILENT TECHNOLOGIES: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 492 AGILENT TECHNOLOGIES: EXPANSIONS, JANUARY 2022-MARCH 2025
  • TABLE 493 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 494 DANAHER CORPORATION: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 495 DANAHER CORPORATION: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 496 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 497 TAKARA BIO INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 498 TAKARA BIO INC.: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 499 ADAPTIVE BIOTECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 500 ADAPTIVE BIOTECHNOLOGIES: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 501 BGI GROUP: COMPANY OVERVIEW
  • TABLE 502 BGI GROUP: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 503 BGI GROUP: PRODUCT LAUNCHES/APPROVALS/UPGRADES, JANUARY 2022-MARCH 2025
  • TABLE 504 BGI GROUP: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 505 BGI GROUP: OTHER DEVELOPMENTS, JANUARY 2022-MARCH 2025
  • TABLE 506 TECAN TRADING AG: COMPANY OVERVIEW
  • TABLE 507 TECAN TRADING AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 508 TECAN TRADING AG: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 509 AZENTA US INC.: COMPANY OVERVIEW
  • TABLE 510 AZENTA US INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 511 PERSONALIS, INC.: COMPANY OVERVIEW
  • TABLE 512 PERSONALIS, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 513 PERSONALIS, INC.: DEALS, JANUARY 2022-MARCH 2025
  • TABLE 514 PERSONALIS, INC.: OTHER DEVELOPMENTS, JANUARY 2022-MARCH 2025
  • TABLE 515 CREATIVE BIOLABS: COMPANY OVERVIEW
  • TABLE 516 CREATIVE BIOLABS: PRODUCTS/SERVICES/SOLUTIONS OFFERED
  • TABLE 517 CELEMICS, INC.: COMPANY OVERVIEW
  • TABLE 518 CELLCARTA: COMPANY OVERVIEW
  • TABLE 519 IREPERTOIRE, INC.: COMPANY OVERVIEW
  • TABLE 520 NEW ENGLAND BIOLABS: COMPANY OVERVIEW
  • TABLE 521 CERBA RESEARCH: COMPANY OVERVIEW
  • TABLE 522 CEGAT GMBH: COMPANY OVERVIEW
  • TABLE 523 ELEMENT BIOSCIENCES: COMPANY OVERVIEW
  • TABLE 524 SEQALIS: COMPANY OVERVIEW
  • TABLE 525 SYNBIO TECHNOLOGIES: COMPANY OVERVIEW
  • TABLE 526 MEDGENOME: COMPANY OVERVIEW
  • TABLE 527 ENPICOM: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 IMMUNE REPERTOIRE SEQUENCING MARKET: SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD
  • FIGURE 2 IMMUNE REPERTOIRE SEQUENCING MARKET: YEARS CONSIDERED
  • FIGURE 3 IMMUNE REPERTOIRE SEQUENCING MARKET: RESEARCH DESIGN
  • FIGURE 4 IMMUNE REPERTOIRE SEQUENCING MARKET: BREAKDOWN OF PRIMARIES
  • FIGURE 5 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2024)
  • FIGURE 6 GLOBAL PRODUCTS MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024)
  • FIGURE 7 GLOBAL SERVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (2024)
  • FIGURE 8 IMMUNE REPERTOIRE SEQUENCING MARKET SIZE VALIDATION FROM PRIMARY SOURCES
  • FIGURE 9 IMMUNE REPERTOIRE SEQUENCING MARKET: TOP-DOWN APPROACH
  • FIGURE 10 IMMUNE REPERTOIRE SEQUENCING MARKET: CAGR PROJECTIONS
  • FIGURE 11 DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION)
  • FIGURE 16 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 17 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 18 IMMUNE REPERTOIRE SEQUENCING MARKET: REGIONAL SNAPSHOT
  • FIGURE 19 INCREASING ADOPTION OF PERSONALIZED MEDICINES AND RISING FOCUS ON GENOMIC RESEARCH TO DRIVE MARKET
  • FIGURE 20 US AND ASSAY KITS & REAGENTS DOMINATED NORTH AMERICAN MARKET IN 2024
  • FIGURE 21 SEQUENCING TECHNOLOGIES TO ACCOUNT FOR LARGEST MARKET SHARE IN 2030
  • FIGURE 22 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES TO COMMAND LARGEST END USER MARKET SHARE IN 2025
  • FIGURE 23 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030
  • FIGURE 24 IMMUNE REPERTOIRE SEQUENCING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 25 IMMUNE REPERTOIRE SEQUENCING MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 26 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER (2024)
  • FIGURE 27 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024 (USD)
  • FIGURE 28 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 29 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 30 IMMUNE REPERTOIRE SEQUENCING MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 31 PATENT APPLICATIONS FOR IMMUNE REPERTOIRE SEQUENCING (JANUARY 2015-DECEMBER 2024)
  • FIGURE 32 IMMUNE REPERTOIRE SEQUENCING MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 33 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS
  • FIGURE 34 KEY BUYING CRITERIA FOR MAJOR END USERS (PRODUCTS MARKET)
  • FIGURE 35 KEY BUYING CRITERIA FOR MAJOR END USERS (SERVICES MARKET)
  • FIGURE 36 FUNDING AND NUMBER OF PROJECTS AND SUB-PROJECTS BY NATIONAL INSTITUTES OF HEALTH, 2021-2025
  • FIGURE 37 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET
  • FIGURE 38 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT
  • FIGURE 39 ASIA PACIFIC: IMMUNE REPERTOIRE SEQUENCING MARKET SNAPSHOT
  • FIGURE 40 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET (2022-2024)
  • FIGURE 41 REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET (2022-2024)
  • FIGURE 42 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, 2024
  • FIGURE 43 MARKET SHARE ANALYSIS OF IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, 2024
  • FIGURE 44 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 45 EV/EBITDA OF KEY PLAYERS
  • FIGURE 46 IMMUNE REPERTOIRE SEQUENCING MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 47 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 48 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY FOOTPRINT
  • FIGURE 49 IMMUNE REPERTOIRE SEQUENCING MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 50 ILLUMINA, INC.: COMPANY SNAPSHOT
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • FIGURE 52 PACBIO: COMPANY SNAPSHOT
  • FIGURE 53 OXFORD NANOPORE TECHNOLOGIES PLC: COMPANY SNAPSHOT
  • FIGURE 54 10X GENOMICS: COMPANY SNAPSHOT
  • FIGURE 55 QIAGEN: COMPANY SNAPSHOT
  • FIGURE 56 AGILENT TECHNOLOGIES: COMPANY SNAPSHOT
  • FIGURE 57 DANAHER CORPORATION: COMPANY SNAPSHOT
  • FIGURE 58 TAKARA BIO INC.: COMPANY SNAPSHOT
  • FIGURE 59 ADAPTIVE BIOTECHNOLOGIES: COMPANY SNAPSHOT
  • FIGURE 60 TECAN TRADING AG: COMPANY SNAPSHOT
  • FIGURE 61 AZENTA US INC.: COMPANY SNAPSHOT
  • FIGURE 62 PERSONALIS, INC.: COMPANY SNAPSHOT